Pico Cell Matrix of ACE Reno and its effect on Adenine induced chronic Kidney disease . Review Article

Chronic Kidney Disease (CKD) is a progressive and multifactorial condition characterized by nephron loss, glomerulosclerosis, tubulointerstitial fibrosis, and vascular compromise. Current therapeutic strategies are largely palliative and fail to address the regenerative deficits underlying CKD. This study explores the safety, effi-cacy, and regenerative potential of ACE Reno, a bioactive Pico Cell Matrix derived from sheep fetal kidney, pla-centa, atrial tissue, and mesenchymal stem cells (MSCs), in an adenine-induced CKD model in Alpine rats. ACE Reno is processed via the ACE Pico Protocol to retain regenerative peptides and signaling molecules while elimi-nating immunogenic material. Histopathological analysis of treated kidneys demonstrated notable improve-ments in glomerular architecture, podocyte integrity, tubular brush border reconstitution, and peritubular capil-lary density. Mechanistically, ACE Reno delivers essential factors that modulate key CKD pathways—suppressing TGF-β and EMT, promoting PGC1-α-mediated mitochondrial repair, enhancing VEGF-A and Ang1-driven angio-genesis, and restoring antifibrotic and anti-inflammatory balance through miRNA modulation (e.g., miR-29 up-regulation). Moreover, the formulation supports podocyte survival via WT1/nephrin signaling and reduces se-nescence-associated secretory phenotypes. These effects collectively arrest the fibrotic cascade, promote nephron regeneration, and improve renal function. The findings position ACE Reno as a promising organ-specific, cell-free therapeutic capable of targeting multiple CKD hallmarks, representing a paradigm shift from conven-tional monotherapy to systemic regenerative intervention. Further studies are warranted to validate these outcomes in larger animal models and clinical trials.